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all patients in the study. For tumours from Vietnamese patients,
hormone-receptor status was analysed by immunohistochemis-
try, using an automated slide stainer (Bench MarkXT, Ventana)
in combination with anti-ER (SP1 250) and anti-PgR (clone 1E2)
rabbit monoclonal antibodies. Tumours with 10% or more stained
nuclei were considered receptor positive. Tumours from Swedish
patients were analysed with an enzyme immunoassay, with a
cut-off point of 0.10 fmol/lg DNA as positive. The hormone-
receptor frequencies between populations were compared
according to clinicopathologic features.
Findings: Compared with Swedish patients with similar meno-
pausal status, the ER-positive rate was higher in premenopausal
Vietnamese patients (71% vs. 58%, p = 0.007) and lower in post-
menopausal Vietnamese patients (45% vs. 72%, p < 0.001). PgR-
positive tumours were found in 58% of premenopausal and 25%
of postmenopausal Vietnamese patients. The corresponding fig-
ures for Swedish patients were 73% and 66%, respectively.
Interpretation: ER positivity in Vietnamese patients decreased
gradually with rising patient age, by contrast with the trend
observed for Swedish patients, who showed a gradual increase
with age. PgR positivity was lower for Vietnamese than for Swed-
ish patients, regardless of age or menopausal status. Our findings
suggest that a high percentage of young patients could benefit
from endocrine therapy, and indicate a limited benefit among
postmenopausal Vietnamese patients.
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Background: SPARC-like protein 1 (SPARCL1) is an extracelluar
matrix glycoprotein involved in many physiological functions.
Studies have shown an important role for SPARCL1 in cancer
development and progression.
Methods: Tissue microarray blocks were constructed based on
1072 Chinese patients, containing gastric-cancer tissue and adja-
cent normal-mucosa tissue. We analysed expression of SPARCL1
from mRNA and at the protein level, using real-time quantitative
polymerase chain reaction (qRT-PCR), semi-quantitative PCR,
immunohistochemistry (IHC), and Western blotting. We analysed
loss of heterozygosity at the SPARCL1 gene locus, using ten
tumour and matched normal-tissue pairs.
Findings: SPARCL1 mRNA was substantially lower in tumour
specimens than in normal tissues. Down-regulation of SPARCL1
protein was detected in 413 (38.7%) of 1072 primary gastric-
tumour tissues. Significant differences in expression were found
according to histological type, tumour size, depth of invasion,
regional lymph-node involvement, TNM stage, and differentia-
tion. Low expression of SPARCL1 was more common in poorly dif-
ferentiated and undifferentiated tumour tissues (51.1%) than in
well and moderately differentiated tumours (29.9%). Kaplan–
Meier survival curves showed that SPARCL1-positive patients
had longer median survival than SPARCL1-negative patients (59
months vs. 28 months, p = 0.001). Our data also showed signifi-
cantly lower 5-year survival for patients with reduced expression
of SPARCL1 (37.8%) than for patients with high expression (49.7%;
p < 0.001). The incidence of loss of heterozygosity for each indi-
vidual marker was 12.5% (1 of 8) for D4S2462, 20% (2 of 10) for
D4S2929 and 33.3% (3 of 9) for SPARCL1.
Interpretation: Our study revealed the clinical significance of
SPARCL1 expression, providing a basis for a novel negative bio-
marker in gastric-cancer progression and prognosis. Further-
more, SPARCL1 protein might be considered a potential
differentiation marker.
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Background: We did a multi-institutional propensity-matched
study comparing video-assisted thoracic surgery (VATS) with
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